Blood Processing Devices MarketSize, Share & Industry Analysis, 2026-2034By ProductBy ApplicationBy End-userBy TechnologyBy Usage

Blood processing devices comprise the equipment and consumables used to collect, separate, store, and monitor human blood and its components, including collection tubes, needles and syringes, collection bags, automated collection and monitoring systems, and lancets. Buyers span hospitals, ambulatory surgical centers and nursing homes, diagnostic and pathology laboratories, and blood banks that manage donor collection, component separation, and inventory for transfusion, therapeutic, and diagnostic use.

The global blood processing devices market stood at USD 54.2 billion in 2025. A forecast-period rate of 7.01% takes it to USD 99.2 billion by 2034, and the study reports every year in between, passing USD 38 billion in 2020, USD 50.3 billion in 2024, USD 57.7 billion in 2026 and USD 75.6 billion in 2030.

On the product axis, growth rates run from 5.07% for Needles & Syringes up to 11.81% for Blood Collection Systems/Monitors. Blood Bags carries the volume: USD 16.26 billion and 30% of revenue in 2025, USD 26.78 billion and 27% in 2034. Share moves toward Blood Collection Systems/Monitors and away from Blood Bags, Blood Collection Tubes, Needles & Syringes and Lancets, though no line shrinks in revenue terms.

By application, Blood Transfusion accounts for 55% of 2025 revenue at USD 29.81 billion, reaching USD 49.6 billion and 50% by 2034. Diagnostic and Research grows faster at 8.31% against 5.82%, moving from 25% of revenue to 28% by 2034. This axis divides the same revenue as the product split instead of adding to it, so the two are read together and never summed.

The regional order runs from North America at 37% of 2025 revenue down to Middle East and Africa at 6%. North America is worth USD 20.05 billion in 2025 and USD 33.73 billion in 2034; Europe, second at 26%, moves from USD 14.09 billion to USD 23.81 billion. Share shifts toward Asia Pacific over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, five product lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global blood processing devices market moves from USD 38 billion in 2020 to USD 54.2 billion in 2025 and USD 99.2 billion by 2034, the forecast period compounding at 7.01% a year.
• 30% of 2025 revenue sits in Blood Bags (USD 16.26 billion) and it remains the largest product line in 2034 at USD 26.78 billion and 27%.
• Blood Collection Systems/Monitors is the fastest-growing line at 11.81%, lifting its share from 16% in 2025 to 24% in 2034 and its revenue from USD 8.67 billion to USD 23.81 billion.
• Against a base case of USD 99.2 billion in 2034, the study also reports a bear case at USD 90.97 billion and a bull case at USD 108.13 billion, with the assumptions behind each set out separately.
• The largest region is North America, generating USD 20.05 billion in 2025 (37% of the global total) and USD 33.73 billion by 2034, ahead of Europe at 26%.
• The United States accounts for 85% of North America in the base year, worth USD 17.04 billion in 2025 and reaching USD 28.67 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Read across the forecast period, the global blood processing devices market shows movement in three places: product composition, regional weight, and the 7.01% rate applied to the whole.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Blood Collection Systems/Monitors grows at more than twice the pace of Needles & Syringes. Between 2026 and 2034, 11.81% growth in Blood Collection Systems/Monitors against 5.07% in Needles & Syringes pulls the product mix apart. Shares follow: 16% to 24% for Blood Collection Systems/Monitors, 20% to 17% for Needles & Syringes. The revenue figures behind that are USD 8.67 billion to USD 23.81 billion and USD 10.84 billion to USD 16.86 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Asia Pacific gain regional share. Asia Pacific moves from 24% of revenue in 2025 to 29% in 2034, worth USD 13.01 billion rising to USD 28.77 billion. Against that, North America at 37% moving to 34%, Europe at 26% moving to 24%, Latin America at 7% moving to 7%, Middle East and Africa at 6% moving to 6%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Fifteen years without a discontinuity. Year by year the total runs USD 38 billion in 2020, USD 50.3 billion in 2024, USD 54.2 billion in 2025, USD 57.7 billion in 2026, USD 75.6 billion in 2030 and USD 99.2 billion in 2034. Against 7.37% through the historical period, the 7.01% forecast rate is a continuation; no year in the series interrupts it. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the product and regional sections come in.

Blood Collection Systems/Monitors carries the market's growth rate

Growth in the global blood processing devices market comes from three measurable sources over 2026-2034: the market's own compounding at 7.01%, the share gained by faster-growing product lines, and expansion in the regions taking a larger part of global revenue.

Downside case: USD 90.97 billion by 2034, against USD 99.2 billion in the base case

What the bull case turns on

One product line carries the market

In North America, 37% of global revenue puts 2025 at USD 20.05 billion and reaches USD 33.73 billion by 2034. Among the five regions it ranks first by revenue in both years.

By 2034 the share stands at 34%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product mix reported at global level applies here, with Blood Bags the largest line at 30% of 2025 revenue and Blood Collection Systems/Monitors the fastest-growing at 11.81%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 17.04 billion in 2025 and projected to reach USD 28.67 billion by 2034. At 85% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 20.05 billion to USD 33.73 billion over the same period, and this is the market carrying the country-level detail in the full report.

The product pattern in the United States is the global one: 30% of 2025 revenue in Blood Bags, 27% by 2034, against 11.81% growth in Blood Collection Systems/Monitors taking it from 16% to 24%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own product breakdown in the full report.

Blood processing devices sold in the United States are regulated by the Food and Drug Administration's Center for Devices and Radiological Health under the Federal Food, Drug, and Cosmetic Act. Most blood collection, separation, and apheresis systems are classified as moderate to high risk and require premarket clearance or approval before a manufacturer can market them, with devices tied directly to blood establishment operations often subject to the stricter biologics license pathway overseen jointly with the Center for Biologics Evaluation and Research. Manufacturers must operate under the Quality System Regulation, register their facilities, and list their devices. Labelling must disclose intended use, storage conditions, and compatibility with blood bags and anticoagulant solutions, and conformity with recognized consensus standards for blood collection and processing equipment is expected as part of a complete submission.

Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US) are the suppliers covered in the United States. Two different problems sit on the same axis: holding Blood Bags at 30% of 2025 revenue, and taking Blood Collection Systems/Monitors while it grows at 11.81%. Per-company positioning and share at country level are in the full report only.

Canada is sized at USD 3.01 billion in 2025, rising to USD 5.06 billion by 2034; 5.6% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

Europe holds 26% of the global blood processing devices market in 2025, worth USD 14.09 billion on the way to USD 23.81 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 24%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Blood Bags largest at 30% of 2025 revenue, Blood Collection Systems/Monitors fastest at 11.81%. Per-axis and per-country detail for Europe sits in the full report.

Germany is the largest market within Europe, generating USD 4.23 billion in 2025 and projected to reach USD 7.14 billion by 2034. 30% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 14.09 billion to USD 23.81 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Blood Bags at 30% of 2025 revenue, easing to 27% by 2034, and the fastest is Blood Collection Systems/Monitors at 11.81%, from 16% to 24%. Since 30% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Germany carries its own product breakdown in the full report.

In Germany, blood processing devices fall under the European Union Medical Device Regulation, enforced domestically through the Medical Devices Act and overseen by the Federal Institute for Drugs and Medical Devices alongside notified bodies that conduct conformity assessment. Devices used in blood collection, separation, and component processing are generally classified in the higher risk tiers given their contact with blood destined for transfusion, requiring a technical file, clinical evaluation, and a CE mark before sale. Manufacturers must also meet the German Transfusion Act's requirements where a device interfaces with blood establishment quality systems. Labelling must be provided in German, state intended use and handling conditions clearly, and conformity with harmonized standards covering sterility, biocompatibility, and mechanical safety is a precondition for market access.

In Germany the field is Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US). The commercially relevant division is 30% of 2025 revenue in Blood Bags, where the volume is, against 11.81% growth in Blood Collection Systems/Monitors, where share moves. That makes Europe a 26% share of 2025 global revenue, USD 14.09 billion rising to USD 23.81 billion, for any supplier deciding where to concentrate.

6.5% of global revenue is generated in the United Kingdom; USD 3.52 billion in 2025, reaching USD 5.95 billion in 2034, and 25% of Europe.

Within Europe, France accounts for 20% of regional revenue and 5.2% of the global total, worth USD 2.82 billion in 2025 and USD 4.76 billion by 2034.

Asia Pacific holds 24% of the global blood processing devices market in 2025, worth USD 13.01 billion with USD 28.77 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 29% over the forecast period, so the region grows faster than the market's 7.01% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Blood Bags largest at 30% of 2025 revenue, Blood Collection Systems/Monitors fastest at 11.81%. Per-axis and per-country detail for Asia Pacific sits in the full report.

China is the largest market within Asia Pacific, generating USD 4.55 billion in 2025 and projected to reach USD 10.07 billion by 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 13.01 billion to USD 28.77 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Blood Bags at 30% of 2025 revenue, easing to 27% by 2034, and the fastest is Blood Collection Systems/Monitors at 11.81%, from 16% to 24%. Since 35% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports China by product separately.

China regulates blood processing devices through the National Medical Products Administration under its medical device classification framework. Devices that come into direct contact with blood intended for transfusion or component separation are typically placed in the higher classification categories, requiring registration approval before domestic sale and, for many products, local clinical evaluation or trial data specific to Chinese patients. Manufacturers, including those importing from abroad, must appoint a domestic agent and demonstrate compliance with national standards covering material safety, sterilization, and performance. Labelling and instructions must appear in Chinese and specify intended use, storage, and compatibility requirements. Facilities producing these devices must also operate under a quality management system aligned with national good manufacturing practice requirements before registration can be granted.

Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US) are the suppliers covered in China. Volume sits in Blood Bags at 30% of 2025 revenue; movement sits in Blood Collection Systems/Monitors at 11.81% growth. That makes Asia Pacific a 24% share of 2025 global revenue, USD 13.01 billion rising to USD 28.77 billion, for any supplier deciding where to concentrate.

Within Asia Pacific, Japan accounts for 25% of regional revenue and 6% of the global total, worth USD 3.25 billion in 2025 and USD 6.33 billion by 2034.

3.6% of global revenue is generated in India; USD 1.95 billion in 2025, reaching USD 5.18 billion in 2034, and 15% of Asia Pacific.

USD 3.79 billion of 2025 revenue is generated in Latin America, 7% of the global blood processing devices market with USD 6.94 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 7%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the product split tracks the global one; 30% of 2025 revenue in Blood Bags, fastest growth of 11.81% in Blood Collection Systems/Monitors. Per-axis and per-country detail for Latin America sits in the full report.

Brazil is the largest market within Latin America, generating USD 1.71 billion in 2025 and projected to reach USD 3.12 billion by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 3.79 billion in 2025 and USD 6.94 billion in 2034, it is the country the full report breaks out in detail.

Brazil buys along the same lines as the market globally; Blood Bags first at 30% of 2025 revenue and 27% in 2034, Blood Collection Systems/Monitors fastest at 11.81% on a share moving from 16% to 24%. Because the country carries 45% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product for Brazil is reported separately in the full report.

Brazil's health surveillance agency, ANVISA, governs the approval and marketing of blood processing devices under its medical device regulatory framework. Products used for blood collection, separation, or component processing are generally classified according to the risk they pose to donors and recipients, with higher risk categories requiring a full registration dossier that includes technical and safety documentation before a device can be sold. Manufacturing sites, whether domestic or foreign, must demonstrate compliance with Brazil's good manufacturing practice certification, which ANVISA verifies through inspection or recognition of an equivalent foreign audit. Labelling must be presented in Portuguese and include intended use, handling instructions, and storage conditions, and conformity with applicable national and international standards for blood-contact equipment is expected throughout the registration process.

In Brazil the field is Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US). Volume sits in Blood Bags at 30% of 2025 revenue; movement sits in Blood Collection Systems/Monitors at 11.81% growth. A supplier weighted toward Latin America is competing over a base of USD 3.79 billion in 2025 reaching USD 6.94 billion by 2034, 7% of global revenue at the start of that period.

Within Latin America, Mexico accounts for 30% of regional revenue and 2.1% of the global total, worth USD 1.14 billion in 2025 and USD 2.08 billion by 2034.

USD 3.25 billion of 2025 revenue is generated in Middle East and Africa, 6% of the global blood processing devices market on the way to USD 5.95 billion by 2034. Among the five regions it ranks fifth by revenue in both years.

6% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The product mix reported at global level applies here, with Blood Bags the largest line at 30% of 2025 revenue and Blood Collection Systems/Monitors the fastest-growing at 11.81%. The full report breaks Middle East and Africa out along every axis and by country.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 1.14 billion in 2025 and USD 2.08 billion in 2034. At 35% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 3.25 billion and USD 5.95 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in Saudi Arabia follows the product mix reported at global level: Blood Bags is the largest line at 30% of 2025 revenue, moving to 27% by 2034, while Blood Collection Systems/Monitors grows fastest at 11.81% and takes its share from 16% to 24%. Because the country carries 35% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own product breakdown in the full report.

The Saudi Food and Drug Authority regulates blood processing devices in Saudi Arabia through its medical device marketing authorization system, which draws on the Gulf-wide harmonized framework for device classification and conformity assessment. Devices used in blood collection or component separation are assessed according to risk level, and manufacturers must register both the device and the local authorized representative before distribution is permitted. Conformity with recognized international standards for blood-contact equipment, sterility, and performance is required as supporting evidence within the registration file. Labelling must be provided in Arabic alongside English, state intended use and storage conditions plainly, and importers must maintain traceability records so that any safety concern raised after market entry can be tracked back to the responsible supplier.

Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US) are the suppliers covered in Saudi Arabia. Blood Bags, at 30% of 2025 revenue, is where the volume sits, and Blood Collection Systems/Monitors, growing at 11.81%, is where position changes hands over the forecast period. A supplier weighted toward Middle East and Africa is competing over a base of USD 3.25 billion in 2025 reaching USD 5.95 billion by 2034, 6% of global revenue at the start of that period.

1.5% of global revenue is generated in South Africa; USD 0.81 billion in 2025, reaching USD 1.49 billion in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Application, End-User, Technology, Usage, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.